SCHEMBL4125314

SCHEMBL4125314

CC(=O)NC1[C@H](O[C@@H]2C(CO)O[C@@H](C)C(NC(C)=O)[C@H]2O)OC(CO)[C@@H](O[C@@H]2OC(CO[C@H]3OC(CO)[C@@H](O)[C@H](O)C3O)[C@@H](O)[C@H](O[C@H]3OC(CO)[C@@H](O)C(O)C3O[C@@H]3OC(CO)[C@@H](O[C@@H]4OC(CO)[C@H](O)[C@H](O[C@]5(OC=O)C[C@@H](O)[C@@H](C)C([C@H](O)[C@H](O)CO)O5)C4O)[C@H](O)C3NC(C)=O)C2O)[C@@H]1O

nearest known ligand 0.50

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SELE P16581 4/20 0.50
▸ SIGLEC7 Q9Y286 6/20 0.48
▸ MAG P20916 7/20 0.46
▸ SELL P14151 2/20 0.42
▸ SELP P16109 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17195832 1.00 SELE (0.50) SELESIGLEC7MAGSELLSELP
SCHEMBL17211073 1.00 SELE (0.50) SELESIGLEC7MAGSELLSELP
SCHEMBL12197074 1.00 SELE (0.50) SELESIGLEC7MAGSELLSELP
SCHEMBL16232779 1.00 SELE (0.50) SELESIGLEC7MAGSELLSELP
SCHEMBL16312016 1.00 SELE (0.50) SELESIGLEC7MAGSELLSELP
SCHEMBL15849101 1.00 SELE (0.50) SELESIGLEC7MAGSELLSELP
SCHEMBL16232775 0.99 SELE (0.48) SELESIGLEC7MAGSELLSELP
SCHEMBL16232778 0.99 SELE (0.48) SELESIGLEC7MAGSELLSELP
SCHEMBL4125500 0.99 SELE (0.48) SELESIGLEC7MAGSELLSELP
SCHEMBL12197072 0.99 SELE (0.48) SELESIGLEC7MAGSELLSELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9937264-B2 Glycosylated polypeptide and drug composition containing said polypeptide GLYTECH, INC. (JP) 2018-04-10 — — US disclosed
US-9802996-B2 Glycosylated polypeptide and drug composition containing said polypeptide GLYTECH, INC. (JP) 2017-10-31 — — US disclosed
US-20170157260-A1 Glycosylated Polypeptide and Drug Composition Containing said Polypeptide GLYTECH, INC. (JP) 2017-06-08 — — US disclosed
US-20160368961-A1 Glycosylated Polypeptide and Drug Composition Containing said Polypeptide GLYTECH, INC. (JP) 2016-12-22 — — US disclosed
US-9441024-B2 Glycosylated polypeptide and drug composition containing said polypeptide GLYTECH, INC. (JP) 2016-09-13 — — US disclosed
US-20140315800-A1 Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide GLYTECH, INC. (JP) 2014-10-23 — — US disclosed
US-20120114595-A1 SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME OTSUKA CHEMICAL CO., LTD. (JP) 2012-05-10 — — US disclosed
US-20110313136-A1 IgG-Fc FRAGMENT AND PROCESS FOR PRODUCING THE SAME OTSUKA CHEMICAL CO., LTD. (JP) 2011-12-22 — — US disclosed
US-20110195897-A1 GLYCOSYLATED GLP-1 PEPTIDE OTSUKA CHEMICAL CO., LTD. (JP) 2011-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313136-A1 IgG-Fc FRAGMENT AND PROCESS FOR PRODUCING THE SAME FCGR1A, FCGR2A, FCGR3B SELE 532/4885SIGLEC7 11/4885MAG 332/4885
US-20110195897-A1 GLYCOSYLATED GLP-1 PEPTIDE GLP1R, GIPR, IAPP SELE 200/4885SIGLEC7 102/4885MAG 1399/4885
US-20170157260-A1 Glycosylated Polypeptide and Drug Composition Containing said Polypeptide GIPR, SSTR4, SSTR3 SELE 428/4885SIGLEC7 100/4885MAG 784/4885
US-20120114595-A1 SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME SIGLEC7, ENGASE, SIGLEC9 SELE 50/4885SIGLEC7 1/4885MAG 319/4885
US-20160368961-A1 Glycosylated Polypeptide and Drug Composition Containing said Polypeptide GIPR, SSTR3, SSTR4 SELE 440/4885SIGLEC7 92/4885MAG 766/4885
US-20140315800-A1 Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide GIPR, SSTR3, SSTR4 SELE 440/4885SIGLEC7 92/4885MAG 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback